Candriam S.C.A. Takes Position in BioCryst Pharmaceuticals, Inc. $BCRX

Candriam S.C.A. acquired a new position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) in the first quarter, HoldingsChannel.com reports. The institutional investor acquired 2,286,841 shares of the biotechnology company’s stock, valued at approximately $21,771,000.

Several other institutional investors have also recently made changes to their positions in BCRX. RA Capital Management L.P. bought a new stake in BioCryst Pharmaceuticals during the 4th quarter valued at approximately $123,452,000. Deerfield Management Company L.P. boosted its stake in BioCryst Pharmaceuticals by 159.4% in the 3rd quarter. Deerfield Management Company L.P. now owns 12,169,000 shares of the biotechnology company’s stock worth $92,363,000 after purchasing an additional 7,477,000 shares during the period. Janus Henderson Group PLC grew its holdings in BioCryst Pharmaceuticals by 7,807.2% during the 4th quarter. Janus Henderson Group PLC now owns 7,404,386 shares of the biotechnology company’s stock valued at $57,791,000 after buying an additional 7,310,745 shares in the last quarter. Perceptive Advisors LLC purchased a new stake in BioCryst Pharmaceuticals during the 4th quarter valued at approximately $24,668,000. Finally, RFG Advisory LLC bought a new stake in shares of BioCryst Pharmaceuticals during the first quarter valued at approximately $27,329,000. Hedge funds and other institutional investors own 85.88% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on the stock. Needham & Company LLC dropped their price objective on shares of BioCryst Pharmaceuticals from $18.00 to $16.00 and set a “buy” rating on the stock in a research note on Wednesday, May 6th. Citizens Jmp upped their target price on BioCryst Pharmaceuticals from $25.00 to $28.00 and gave the stock a “market outperform” rating in a report on Thursday, May 7th. Wedbush dropped their target price on BioCryst Pharmaceuticals from $22.00 to $21.00 and set an “outperform” rating on the stock in a research report on Thursday, May 7th. Wall Street Zen downgraded BioCryst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Saturday, May 9th. Finally, Cantor Fitzgerald lifted their price target on BioCryst Pharmaceuticals from $27.00 to $29.00 and gave the company an “overweight” rating in a report on Tuesday, June 30th. Eight research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $21.78.

BioCryst Pharmaceuticals Trading Down 2.5%

Shares of BCRX traded down $0.27 during midday trading on Friday, hitting $10.45. 3,359,241 shares of the company’s stock traded hands, compared to its average volume of 6,231,274. BioCryst Pharmaceuticals, Inc. has a 1 year low of $6.00 and a 1 year high of $11.22. The firm’s fifty day moving average is $9.14 and its 200-day moving average is $8.44. The stock has a market capitalization of $2.66 billion, a price-to-earnings ratio of -5.87 and a beta of 0.55.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its earnings results on Wednesday, May 6th. The biotechnology company reported ($2.98) earnings per share for the quarter, missing the consensus estimate of $0.06 by ($3.04). BioCryst Pharmaceuticals had a negative return on equity of 76.36% and a negative net margin of 51.71%.The business had revenue of $156.41 million for the quarter, compared to analysts’ expectations of $151.12 million. During the same quarter last year, the firm earned $0.20 earnings per share. The firm’s quarterly revenue was up 7.5% compared to the same quarter last year. On average, equities research analysts anticipate that BioCryst Pharmaceuticals, Inc. will post -2.61 EPS for the current year.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.